Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Ashler et Manson's Days Sales Outstanding for the
six
months ended in Dec. 2024 was 476.03.
Ashler et Manson's Days Inventory for the
six
months ended in Dec. 2024 was 0.
Ashler et Manson's Days Payable for the
six
months ended in Dec. 2024 was 133.18.
Therefore, Ashler et Manson's Cash Conversion Cycle (CCC) for the
six
months ended in Dec. 2024 was 342.85.
Ashler et Manson (XPAR:MLAEM) Cash Conversion Cycle Explanation
Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.
Be Aware
CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.
The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.
Ashler et Manson Cash Conversion Cycle Related Terms
Ashler et Manson Cash Conversion Cycle Historical Data
* Premium members only.
The historical data trend for Ashler et Manson's Cash Conversion Cycle can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XPAR:MLAEM vs MRSH, AON, AJG: Cash Conversion Cycle Comparison
For the Insurance Brokers subindustry, Ashler et Manson's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ashler et Manson Cash Conversion Cycle vs Insurance Industry
For the Insurance industry and Financial Services sector, Ashler et Manson's Cash Conversion Cycle distribution charts can be found below:
* The bar in red indicates where Ashler et Manson's Cash Conversion Cycle falls into.
Ashler et Manson Cash Conversion Cycle Calculation
Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.
Cash Conversion Cycle is one of several measures of management effectiveness.
Ashler et Manson's Cash Conversion Cycle for the fiscal year that ended in Dec. 2024 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ashler et Manson (XPAR:MLAEM) has a Cash Conversion Cycle of 342.85 as of Dec. 2024. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Ashler et Manson and its competitors.
Is Ashler et Manson's Cash Conversion Cycle too high?
Ashler et Manson's current Cash Conversion Cycle is 342.85. The Insurance industry median Cash Conversion Cycle is 5.28. Ashler et Manson's value of 342.85 is 6393.4% above this industry median. Overall, Ashler et Manson has a GF Score™ of 80/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Ashler et Manson's Cash Conversion Cycle compare to MRSH and AON?
Ashler et Manson's Cash Conversion Cycle of 342.85 can be compared against companies in the Insurance industry. The industry median Cash Conversion Cycle is 5.28. Ashler et Manson's value of 342.85 is 6393.4% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Conversion Cycle for an Insurance company?
The median Cash Conversion Cycle among Insurance companies is 5.28, based on 65 companies in the industry. Companies in the top quartile (top 25%) have a Cash Conversion Cycle significantly above this median, while those in the bottom quartile fall well below. However, Cash Conversion Cycle should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ashler et Manson's current Cash Conversion Cycle of 342.85 is 6393.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Conversion Cycle mean?
A high Cash Conversion Cycle can signal that a stock is expensive relative to its fundamentals. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Ashler et Manson and its competitors. For the Insurance industry, the median Cash Conversion Cycle is 5.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ashler et Manson's current Cash Conversion Cycle is 342.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ashler et Manson stock overvalued right now?
Based on GuruFocus' analysis, Ashler et Manson (XPAR:MLAEM) is currently considered Modestly Overvalued. The stock's GF Value™ is €2.62, compared to a current price of €3.04 — trading 16% above its estimated fair value. The current Cash Conversion Cycle is 342.85 and 6393.4% above the Insurance industry median of 5.28. Ashler et Manson's overall GF Score™ is 80/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Conversion Cycle calculated?
Cash Conversion Cycle is calculated from a company's financial statements. For Ashler et Manson (XPAR:MLAEM), the current Cash Conversion Cycle is 342.85 as of Dec. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ashler et Manson (XPAR:MLAEM) Overvalued in 2026?
Based on GuruFocus' analysis, Ashler et Manson stock appears to be overvalued.
The current stock price of €3.04 is trading 16% above its estimated GF Value™ of €2.62.
GuruFocus considers Ashler et Manson to be Modestly Overvalued.
Key valuation signals for XPAR:MLAEM:
Cash Conversion Cycle: 342.85
GF Value™: €2.62 vs. price of €3.04 (16% above fair value)
Industry Position: 6393.4% above the Insurance median
No single metric tells the full story. See the XPAR:MLAEM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XPAR:MLAEM has been successfully added to your 
